Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC

Inclusion criteria

• Age > 18 years old, male and female;
• According to the Guidelines for the Diagnosis and Treatment of Primary Lung Cancer (2022 edition), the patient was diagnosed with NSCLC by imaging and histopathology;
• TNM stages were III-IV;
• Newly diagnosed, first-line treatment failure, refusal or inability to perform conventional treatment (surgery, chemoradiotherapy);
• ECOG PS ≤2;
• Expected survival > 3 months;
• Sign the informed consent voluntarily, and the compliance is good.

Exclusion criteria

• Previously received interventional therapy (iodine particle implantation, ablation, TACE treatment);
• Combined with extensive and uncontrolled extrapulmonary metastases, such as liver metastasis, bone metastasis, and brain metastasis;
• Have had or currently having other primary malignant tumors;
• White blood cell < 3×109/L, platelet count < 50×109/L, HGB < 90 g/L;
• Hepatic and renal insufficiency (creatinine > 2 mg/L; AST and/or ALT > 2 times the normal upper limit);
• Coagulation dysfunction (INR > 1.5) or known bleeding disease (except lung cancer combined with hemoptysis), or anticoagulation therapy;
• Patients with active infection requiring antibiotic treatment;
• Uncontrolled hypertension, diabetes, and cardiovascular disease with obvious symptoms;
• contrast agent allergy;
• Women with pregnancy or lactation.